全文获取类型
收费全文 | 4425篇 |
免费 | 373篇 |
国内免费 | 227篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 46篇 |
妇产科学 | 47篇 |
基础医学 | 853篇 |
口腔科学 | 282篇 |
临床医学 | 315篇 |
内科学 | 830篇 |
皮肤病学 | 81篇 |
神经病学 | 198篇 |
特种医学 | 57篇 |
外国民族医学 | 2篇 |
外科学 | 307篇 |
综合类 | 544篇 |
现状与发展 | 1篇 |
预防医学 | 80篇 |
眼科学 | 27篇 |
药学 | 799篇 |
1篇 | |
中国医学 | 67篇 |
肿瘤学 | 466篇 |
出版年
2024年 | 13篇 |
2023年 | 79篇 |
2022年 | 121篇 |
2021年 | 179篇 |
2020年 | 161篇 |
2019年 | 155篇 |
2018年 | 157篇 |
2017年 | 137篇 |
2016年 | 128篇 |
2015年 | 164篇 |
2014年 | 273篇 |
2013年 | 367篇 |
2012年 | 272篇 |
2011年 | 332篇 |
2010年 | 250篇 |
2009年 | 242篇 |
2008年 | 267篇 |
2007年 | 260篇 |
2006年 | 231篇 |
2005年 | 180篇 |
2004年 | 189篇 |
2003年 | 145篇 |
2002年 | 120篇 |
2001年 | 111篇 |
2000年 | 90篇 |
1999年 | 67篇 |
1998年 | 84篇 |
1997年 | 46篇 |
1996年 | 44篇 |
1995年 | 37篇 |
1994年 | 25篇 |
1993年 | 19篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 9篇 |
1987年 | 5篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 1篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有5025条查询结果,搜索用时 0 毫秒
11.
Raymond G. Goodwin Wenie S. Din Terri Davis-Smith Dirk M. Anderson Steven D. Gimpel Timothy A. Sato Charles R. Maliszewski Camilynn I. Brannan Neal G. Copeland Nancy A. Jenkins Terry Farrah Richard J. Armitage William C. Fanslow Craig A. Smith 《European journal of immunology》1993,23(10):2631-2641
4-1BB is an inducible T cell antigen that shows sequence homology to members of an emerging family of cytokine receptors, including those for tumor necrosis factor and nerve growth factor. To aid in the analysis of the function of 4-1BB we have utilized a soluble form of the molecule as a probe to identify and clone the gene which encodes its ligand. The ligand for 4-1BB is a type II membrane glycoprotein that has homology to tumor necrosis factor, lymphotoxin, and the ligands for CD40 and CD27, all of which are themselves ligands to receptors in this superfamily. The gene for 4-IBB is on mouse chromosome 4 and maps close to the p80 form of the tumor necrosis factor receptor as well as the gene for CD30. The gene for 4-IBB ligand maps to mouse chromosome 17, but considerably distal to the tumor necrosis factor and lymphotoxin genes. Interaction of 4-1BB with its ligand induces the proliferation of activated thymocytes and splenic T cells, a response which is mimicked on similar cell populations stimulated with an antibody to 4-1BB. 相似文献
12.
13.
Innate immunity, macrophage activation, and atherosclerosis 总被引:7,自引:0,他引:7
Summary: Inflammation underpins the development of atherosclerosis. Initiation and progression of vascular inflammation involves a complex cellular network, with macrophages as major contributors. Activated macrophages produce proinflammatory mediators, bridge innate and adaptive immunity, regulate lipid retention, and participate directly in vascular repair and remodeling. Recent efforts to elucidate molecular mechanisms involved in the regulation of vascular inflammation in atherosclerosis have implicated several families of innate immune recognition receptors in inflammatory activation during the course of this disease. This article reviews our current understanding of innate immune recognition receptors, signaling pathways, and putative ligands implicated in activation of macrophages in the disease. In its final section, we propose a model for the role of macrophages in bridging inflammation and atherosclerosis from the perspective of innate immune recognition and activation. 相似文献
14.
Martin Steegmaier James E. Blanks Eric Borges Dietmar Vestweber 《European journal of immunology》1997,27(6):1339-1345
It has been shown recently that mast cells play an essential role as a source of tumor necrosis factor-α production during neutrophil recruitment to sites of bacterial infection. Increased numbers of mast cells are indeed noted at sites of wound healing and inflammation. These cells are either recruited from the bone marrow or proliferate locally under cytokine stimulation. Little is known about how mast cell progenitors extravasate into tissue. Using antibody-like fusion proteins of mouse E-selectin and P-selectin, we have analyzed the ability of immature mouse bone marrow-derived mast cells (BMMC) to interact with the endothelial selectins. The P-selectin glycoprotein ligand-1 (PSGL-1) was affinity-isolated from detergent extracts of surface biotinylated BMMC with both selectin-IgG fusion proteins. However, only P-selectin-IgG, but not E-selectin-IgG showed significant interaction with intact BMMC as tested by flow cytometry and cell attachment assays with the immobilized fusion proteins under flow and non-flow conditions at physiological shear stress. Thus, in spite of carrying the necessary carbohydrate modifications which enable solubilized PSGL-1 to bind avidly to E-selectin, PSGL-1 on the surface of BMMC is presented in a way that prevents it from interacting efficiently with E-selectin. Affinity-purified rabbit antibodies against mouse PSGL-1 almost completely blocked the interaction of BMMC with P-selectin-IgG in flow cytometry as well as in cell adhesion assays under static and under flow conditions. Our data reveal that PSGL-1 is the major binding site for P-selectin on mouse BMMC progenitors, but does not support efficient interactions with E-selectin. 相似文献
15.
文章通过特异的引物分别扩增出CTLA 4和FasL胞外区的cDNA ,将它们拼接后 ,克隆入真核表达载体pcDNA3 1( + )中 ,进行表达、纯化 ,获得CTLA 4 FasL融合蛋白。Westernblot分析显示了该融合蛋白具有CTLA4 胞外区和FasL胞外区的抗原性。体外试验表明 ,该融合蛋白可以结合Jurkat细胞表面的Fas受体和Raji细胞表面的B7分子 ,表明了该分子双特异性的特点。该融合蛋白能够直接诱导Jurkat细胞发生凋亡 ,且此凋亡效应伴随Raji细胞的参与而增强 ,初步证实了该分子的免疫抑制效应 ,从而为进一步研究该融合蛋白特性及应用奠定了基础。 相似文献
16.
17.
T. Neumann P. Oelzner P. K. Petrow K. Thoss G. Hein G. Stein R. Bräuer 《Inflammation research》2006,55(1):32-39
Objective: To assess the effect of osteoprotegerin (OPG) on joint swelling, synovial inflammation and cartilage destruction, periarticular
and axial bone volume, and bone turnover in rat antigen-induced arthritis (AIA). Design: Rats were treated with OPG (3 mg/kg/day) at regular intervals from day 1 to day 20 of AIA. Disease activity was evaluated
by measurement of joint swelling as well as, joint inflammation and destruction by histology. Bone volume and cellular turnover
parameters of secondary spongiosa of the right tibia head and the third lumbar vertebra were evaluated by histomorphometry.
Periarticular bone volume of the primary spongiosa at the right tibia head was measured by linear scanning. The findings were
compared with those of PBS-treated AIA and healthy animals. Result: OPG treatment did not reduce joint swelling or histological signs of inflammation. Cartilage destruction was reduced. However,
this effect did not reach statistical significance . In the secondary spongiosa OPG treatment reduced the loss of periarticular
bone volume. However, the latter did not reach the level of healthy controls. OPG treatment significantly reduced parameters
of bone formation and bone resorption. In the primary spongiosa, OPG-treatment led to a higher amount of mineralized tissue
and a greater number of trabeculae compared to PBS-treated animals with AIA or healthy controls. In the axial skeleton, OPG
treatment reduced bone formation and bone resorption parameters compared to healthy animals. This treatment had no influence
on bone volume. Conclusions: In periarticular bone of AIA rats, OPG treatment reduced the loss of bone volume and decreased the bone turnover, thus preventing
periarticular bone destruction. OPG treatment had no influence on inflammatory process or on cartilage destruction.
Received 2 June 2005; returned for revision 26 July 2005; returned for final revision 9 August 2005; accepted by M. Parnham
24 September 2005
Presented in part at the 66. Annual Meeting of the American College of Rheumatology, New Orleans, U.S.A., October 2002, and
at the 25. Annual Meeting of the American Society of Bone and Mineral Research, Minneapolis, USA, September 2003
Supported by grants from the Thuringian Ministry of Science, Research and Art (B307-01025, B378-01017), the Interdisciplinary
Center for Clinical Research (IZKF) Jena, and the Deutsche Forschungsgemeinschaft (Br 1372/5-1)
Osteoprotegerin was generously provided by Amgen (Thousand Oaks, CA, USA).
Drs. Neumann and Oelzner contributed equally to this work. 相似文献
18.
Florry A. Vyth-Dreese Trees A. M. Dellemijn Donn Majoor Daphne de Jong 《European journal of immunology》1995,25(11):3023-3029
Functional interactions between B and T lymphocytes are known to depend on the expression of co-stimulatory molecules B7.1/CD80, B7.2/CD86 and their counter-receptors CD28 and CTLA4, as well as CD40 and its ligand CD40L. To study the role of these molecules in situ, an immunohistochemical analysis was carried out on normal human lymphoid tissue. In the germinal centers (GC), B7.1 and B7.2 were differentially expressed. In the dark zone, centroblasts were predominantly B7.1+, while centrocytes in the light zone were B7-2+, resulting in reversed gradients of both markers in GC. Follicle mantle cells were negative for B7.1 and B7.2. Macrophages and interdigitating dendritic cells (IDC) in T cell zones both expressed B7.1 and B7.2. Moreover, clusters of B7.2+ T cells were demonstrated in interfollicular areas. Intrafollicular CD4+ T cells in GC, predominantly in the apical light zone, expressed CD28 and CTLA4, as did the majority of interfollicular T cells. CTLA4 showed a striking excentric cytoplasmic staining, which was also seen on T cells activated in vitro. CD40 was expressed on all B cells and more strongly on macrophages and IDC. Moreover, small clusters of T cells in a rim outside the GC showed CD40 expression. CD40L was expressed both on intrafollicular CD4+ T cells as well as on T cells in T cell zones. The differential distribution of co-stimulatory molecules in different compartments of normal human lymphoid tissue in situ indicates that these interactions play a distinctive role in different stages of B cell differentiation and in the immune response. 相似文献
19.
20.
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant 总被引:5,自引:0,他引:5
McNeel DG Knutson KL Schiffman K Davis DR Caron D Disis ML 《Journal of clinical immunology》2003,23(1):62-72
A pilot vaccine study was conducted to test the safety and immunological efficacy of four monthly immunizations of an MHC class I peptide vaccine, the E75 HLA-A2 epitope from HER-2/neu, using flt3 ligand as a systemic vaccine adjuvant. Twenty HLA-A2-expressing subjects with advanced stage prostate cancer were randomly assigned to one of four immunization or treatment schedules: (a) Flt3 ligand (20 g/kg per day) administered subcutaneously daily for 14 days on a 28-day cycle, monthly for four months; (b) flt3 ligand course as above with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle; (c) flt3 ligand course as above with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle; or (d) E75 peptide admixed with granulocyte–macrophage colony-stimulating factor and administered intradermally once every 28 days, as has previously been reported. The primary endpoints of the study were the determination of safety and immunological efficacy in generating E75-specific T cells as determined by peptide-specific interferon-gamma ELIspot. Adverse events included one grade 3 skin reaction and the development of grade 2 autoimmune hypothyroidism in two subjects with preexisting subclinical autoimmune hypothyroidism. Dendritic cells were markedly increased in the peripheral blood of subjects receiving flt3 ligand with each repetitive cycle, but augmentation of antigen-presenting cells within the dermis was not observed. Apart from a single subject, no significant peptide-specific T-cell responses were detected by ELIspot, whereas delayed-type hypersensitivity responses were detectable in control subjects and in subjects receiving peptide vaccine early in the course of flt3 ligand administration. The absence of robust peripheral immune responses in the current study may be attributable to the small numbers of subjects or differences in the subject population. In addition, the inability of flt3 ligand to augment the number of peripheral skin antigen-presenting cells may have contributed to the absence of robust peptide-specific immunity detectable in the peripheral blood of immunized subjects treated with flt3 ligand. 相似文献